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A North Carolinian developed fatal coccidioidomycosis immediately after bilateral lung transplantation. The
donor had previously traveled to Mexico, and the recipient had no travel history to an area where Coccidioides
immitis is endemic. Immunosuppresive therapy of the transplant recipient likely reactivated latent Coccidioides
infection in the donor lungs, leading to posttransplant coccidioidomycosis.
CASE REPORT
A 61-year-old North Carolina resident with chronic obstruc-
tive pulmonary disease and emphysema received a bilateral
lung transplant. Subsequent immunosuppressive therapy in-
cluded methylprednisone, azathioprine, and cyclosporine.
During hospitalization, the patient also received cefuroxime,
clindamycin, piperacillin-tazobactam, and acyclovir as prophy-
laxis, but no antifungal prophylaxis was initiated. Posttrans-
plantation, the patient was poorly responsive and had compli-
cations, including coagulopathy, hypotension, and hypoxia,
resulting in increased oxygen requirements. Laboratory find-
ings were consistent with liver, pancreas, and kidney dysfunc-
tion, and the patient ultimately required hemodialysis. Chest
X-ray images during the first postoperative week indicated
bilateral diffuse pulmonary opacities consistent with edema or
infection.
At 2 weeks posttransplantation, cerebrospinal fluid (CSF)
was obtained. CSF analysis showed 1 red blood cell/mm3 and
1 total nucleated cell/mm3 (22% lymphocytes, 63% monocytes,
15% other cells). The CSF contained 32 mg of protein/dl
(normal, 15 to 45 mg/dl). A glucose level determination was
not performed. The Gram stain showed no polymorphonuclear
leukocytes and no organisms. The CSF culture was reported as
no growth at 7 days, and peripheral blood cultures were neg-
ative after 5 days of incubation. Bronchial washings from the
donor lungs at the time of transplantation grew oxacillin-sus-
ceptible Staphylococcus aureus. Stenotrophomonas maltophilia
and coagulase-negative Staphylococcus spp. were recovered
from subsequent washings. The patient’s chest X-ray images
showed persistent bilateral infiltrates and worsening alveolar
consolidation.
During the third week posttransplantation, chest X-ray im-
ages demonstrated extensive, progressive bilateral air space
and interstitial opacities, as well as bilateral apical and lateral
pleural thickening. In addition, a brain magnetic resonance
image showed multiple areas of enhancement in the region of
the gray-white matter junction thought to be consistent with a
fungal infection. The patient had multiple line-drawn blood
cultures positive with Candida parapsilosis. Further, a KOH
preparation of the patient’s bronchial washing showed budding
yeast with pseudohyphae, and the Gram stain showed poly-
morphonuclear leukocytes and yeast. Interestingly, this culture
not only grew Candida and S. maltophilia but also Coccidioides
immitis. In less than 1 month postoperatively, the patient died,
and an autopsy was performed.
Anatomically, the patient had extensive pneumonia, multi-
ple small abscesses in the spleen, and extensive acute fungal
pericarditis and pyelonephritis. Hematoxylin and eosin and
Gomori’s methenamine silver (GMS) staining of lungs, peri-
cardium, and spleen sections revealed numerous endosporu-
lating spherules consistent with C. immitis (Fig. 1). In addition,
cultures of the spleen and lungs grew C. immitis. GMS staining
of the kidneys and pericardium showed extensive yeast with
pseudohyphae, a finding consistent with Candida. Thus, the
cause of death was likely disseminated coccidioidomycosis and
candidiasis secondary to immunosuppressive therapy post-
transplantation.
The disease coccidioidomycosis is caused by the dimorphic
fungus C. immitis, which is endemic in dry climates such as the
southwestern United States, northern Mexico, and parts of
Central and South America. In the soil, C. immitis exists in a
mycelial state, and the hyphae develop into arthroconidia that
are highly infectious and airborne. Inhaled arthroconidia are
the source of human infection. Once in tissue, C. immitis ar-
throconidia develop into thick-walled spherules, each contain-
ing endospores (Fig. 1). Endospores are released when the
spherule ruptures, and each endospore can develop into a new
spherule, and thus the infection progresses (6).
In immunocompetent individuals, disseminated coccidioid-
omycosis is extremely rare. Infection with C. immitis is usually
subclinical (60%) but may occasionally present as a nonspe-
cific influenza-like syndrome, or less commonly, as pneumonia
(9). It is estimated based on delayed dermal hypersensitivity
testing that, in areas where this organism is endemic, one-third
of the local population are infected with C. immitis (5). Pop-
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ulations that are at risk for developing serious complications
from C. immitis infection include those with diabetes mellitus,
pregnant women, and immunocompromised patients, such as
those at the extremes of age, human immunodeficiency virus-
infected individuals, and transplant recipients (12).
Coccidioidomycosis in transplant patients typically occurs as
a result of either a primary infection posttransplantation in
areas where this organism is endemic or reactivation of latent
infection. The medical literature indicates that reactivation of
latent C. immitis infection likely represents the majority of
coccidioidomycosis posttransplant cases, primarily occurring in
patients who have resided in or visited these areas (2, 3). In
fact, some transplant centers in endemic areas test potential
organ recipients for C. immitis serology and prophylactically
treat those with a positive result or a past history of coccidioi-
dal infection (1). The appearance of coccidioidomycosis due to
reactivation typically occurs in 4 to 6 months posttransplant
(10).
In addition, there are rare reports of transmission due to
infected donor lungs, liver, and kidney (13, 14). Infection from
donor lungs has been reported to develop in the immediate
postoperative period (13). Since the patient reported here was
hospitalized during the entire postoperative period and was a
North Carolina resident, it is unlikely that C. immitis was
acquired as a primary infection posttransplantation. Therefore,
the patient’s fatal coccidioidomycosis most likely developed
due to reactivation of a latent infection, either provided by the
patient’s own latent infection or by the donor lungs. The re-
cipient’s lack of a travel history outside of North Carolina and
the accelerated postoperative course of the coccidioidomycosis
suggest that the donor lungs provided the coccidioidal infec-
tion. The donor was a 30-year-old North Carolina resident
without a significant past medical or travel history. However,
the donor had visited Mexico 2 years prior to organ donation.
The incidence of postoperative fungal infections in lung
transplant recipients is reportedly 15 to 35% (8, 11). In this
patient population, the most commonly isolated fungal organ-
isms are Candida and Aspergillus spp. due to their ubiquity. In
addition, in areas where these organisms are endemic, coccid-
ioidomycosis occurs in 4 to 8% of transplant patients, generally
occurring within the first postoperative year (2, 7). However, in
areas where these organisms are not endemic, the diagnosis of
coccidioidomycosis is often delayed due to a low index of
suspicion (4). Therefore, for solid organ transplant recipients
who reside in an area where this organism is endemic, who
have a positive Coccidioides serology, or who are receiving a
donor organ from a resident such an area, antifungal prophy-
laxis with an azole may be prudent (1, 2). It is also of great
importance for areas where this organism is not endemic,
where Coccidioides serology is not routinely performed, to
establish the patient’s travel history to areas where this organ-
ism is endemic in order to assess the relative risk of coccid-
ioidomycosis due to latent reactivation. Further, as demon-
strated in this case, previous travel history of the donor may
also prove to be beneficial. Broadening the view of the patients
that are at high risk for Coccidioides reactivation and applying
appropriate prophylaxis may prevent the potentially fatal post-
transplant complication of disseminated coccidioidomycosis.
We thank Jun Shen and Charles Jennette for expert analysis of
autopsy findings and for assistance in locating donor information.
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